Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential

Cell Death and Differentiation

Volumn 19, Issue 3, 2012, Pages 428-439

  Heddleston, J M ^a   Wu, Q ^a   Rivera, M ^a   Minhas, S ^a   Lathia, J D ^a   Sloan, A E ^b   Iliopoulos, O ^c   Hjelmeland, A B ^a   Rich, J N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

cancer stem cell; epigenetics; HIF2 ; hypoxia; MLL1

Indexed keywords

CD133 ANTIGEN; HISTONE METHYLTRANSFERASE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MIXED LINEAGE LEUKEMIA PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN 1; OXYGEN; TUBULIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STEM CELL; CARCINOGENICITY; CELL COMPARTMENTALIZATION; CELL HYPOXIA; CELL RENEWAL; CONTROLLED STUDY; GENE EXPRESSION; GENETIC HETEROGENEITY; GLIOBLASTOMA; GLIOMA; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; RNA INTERFERENCE; TUMOR MICROENVIRONMENT;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASTIC STEM CELLS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857042390     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.109     Document Type: Article

References (40)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 2009; 10: 459-466.
2. Hesselager G, Holland EC. Using mice to decipher the molecular genetics of brain tumors. Neurosurgery 2003; 53: 685-694;discussion 695.
3. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009; 4: E7752.
4. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
5. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173. (Pubitemid 43357943)
6. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006; 6: 425-436.
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760. (Pubitemid 44949604)
8. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al. CD133(+) and CD133(+) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015. (Pubitemid 46815044)
9. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010; 6: 421-432.
10. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
11. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
12. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
13. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006; 13: 1238-1241. (Pubitemid 43905604)
14. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82. (Pubitemid 46054518)
15. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 3274-3284.
16. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain J Neurol 2010; 133: 983-995.
17. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28: 3949-3959.
18. Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, Macswords J, Lathia JD et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011; 18: 829-840.
19. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872. (Pubitemid 350138099)
20. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009; 5: 237-241.
21. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009; 27: 40-48.
22. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One 2008; 3: E3769.
23. Guenther MG, Frampton GM, Soldner F, Hockemeyer D, Mitalipova M, Jaenisch R et al. Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell 2010; 7: 249-257.
24. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009; 29: 8884-8896.
25. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007; 12: 328-341. (Pubitemid 47539307)
26. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-833. (Pubitemid 350006257)
27. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: A molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010; 10: 721-728.
28. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10: 257-268. (Pubitemid 44512188)
29. Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009; 4: 129-140.
30. Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol 2006; 13: 713-719. (Pubitemid 44175164)
31. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009; 113: 2375-2385.
32. Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK et al. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 2010; 467: 343-346.
33. Huntsman DG, Chin SF, Muleris M, Batley SJ, Collins VP, Wiedemann LM et al. MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene 1999; 18: 7975-7984. (Pubitemid 30050558)
34. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331: 435-439.
35. Lim DA, Huang YC, Swigut T, Mirick AL, Garcia-Verdugo JM, Wysocka J et al. Chromatin remodelling factor Mll1 is essential for neurogenesis from postnatal neural stem cells. Nature 2009; 458: 529-533.
36. Wang P, Lin C, Smith ER, Guo H, Sanderson BW, Wu M et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol 2009; 29: 6074-6085.
37. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006; 20: 586-600. (Pubitemid 43345324)
38. Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A et al. Small-molecule inhibitors of HIF-2a translation link its 50UTR iron-responsive element to oxygen sensing. Mol cell 2008; 32: 838-848.
39. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-7848. (Pubitemid 44299144)
40. Uemura M, Yamamoto H, Takemasa I, Mimori K, Hemmi H, Mizushima T et al. Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: In vivo identification from hypoxic tumor cells. Clin Cancer Res 2010; 16: 4636-4646.